Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Up 562.1% in March

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 929,600 shares, a growth of 562.1% from the February 28th total of 140,400 shares. Currently, 8.1% of the shares of the stock are short sold. Based on an average trading volume of 14,530,000 shares, the days-to-cover ratio is presently 0.1 days.

Plus Therapeutics Stock Up 2.8 %

Shares of PSTV stock opened at $1.47 on Thursday. Plus Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $2.67. The business has a fifty day simple moving average of $1.10 and a 200-day simple moving average of $1.24. The stock has a market cap of $8.67 million, a P/E ratio of -0.58 and a beta of 0.73.

Analysts Set New Price Targets

Several equities research analysts have commented on PSTV shares. Ascendiant Capital Markets decreased their target price on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, December 9th. D. Boral Capital initiated coverage on shares of Plus Therapeutics in a research note on Monday, March 17th. They issued a “buy” rating and a $9.00 price objective for the company.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.